ABBV · Healthcare
ABBVIE INC
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
44
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$444.5B
Industry
Drug Manufacturers - General
Sector
Healthcare
Exchange
NYSE
About ABBVIE INC
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products;…
Who's behind the signal
Every informed buyer we can see on ABBV, across all three feeds.
Hedge funds · 8
Tudor Investment (Paul Tudor Jones)
New position
AQR Capital Management
Increased +24%
Gotham Asset Mgmt (Greenblatt)
Increased +78%
Polen Capital Management
Unchanged
D.E. Shaw & Co
Decreased −40%
Citadel Advisors
Decreased −76%
+2 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ABBVIE INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
1
New positions
2
Increasing
4
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.1%
Position change
NEW
0.1% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+24%
0.1% of AQR Capital Management's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+78%
0.1% of Gotham Asset Mgmt's portfolio
Trust weight: 1.3×
% of portfolio
0.2%
Position change
—
0.2% of Polen Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−40%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−76%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
−94%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−99%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ABBVIE INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ABBVIE INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime